Terminated PHASE2 INTERVENTIONAL 2-arm NCT00979550

The Effects of Aldara as an Adjunct to Laser Treatment

The Effects of Aldara as an Adjunct to Laser Treatment of Port Wine Stains

Sponsor: Graceway Pharmaceuticals, LLC

Interventions Imiquimod non-medicated petroleum cream

Updated 9 times since 2017 Last updated: Mar 19, 2018 Started: Oct 31, 2008 Primary completion: Aug 31, 2013 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Failure to enroll enough participants

Other terminated trials from Graceway Pharmaceuticals, LLC

Actinic Keratosis · Phase PHASE4 · Nov 2011

More terminations from Graceway Pharmaceuticals, LLC

Listed as NCT00979550, this PHASE2 trial focuses on Port Wine Stains and remains terminated or withdrawn. Sponsored by Graceway Pharmaceuticals, LLC, it has been updated 9 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Apr 2018 — Jun 2018 [monthly]

Terminated PHASE2

Status: Completed → Terminated
Feb 2017 — Apr 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Graceway Pharmaceuticals, LLC
Henry Vasconez

Data source: University of Kentucky

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lexington, United States